Roivant Sciences P/E-luku 2024

Mitä Roivant Sciences tekee?

Roivant Sciences Ltd is a biopharmaceutical company based in Basel, Switzerland. It was founded in 2014 by Vivek Ramaswamy, a former hedge fund manager. The company's idea was to develop "orphan molecules," which are drug compounds that have not been further developed by large pharmaceutical companies for various reasons. Roivant Sciences' business model is based on identifying therapy areas with high unmet medical needs. It then collaborates with academic institutions and other partners to search for orphan molecules that could be potentially interesting for these therapy areas. The molecules are further developed in the company's internal research and development laboratories. Roivant Sciences has established seven different subsidiary companies through its innovative approach to drug development and acquisition of other companies. Some of the most well-known subsidiaries include Axovant Sciences, Dermavant Sciences, Enzyvant Therapeutics, and Myovant Sciences. Each subsidiary of Roivant Sciences focuses on specific therapy areas. For example, Axovant Sciences focuses on developing therapies for neurological diseases such as Parkinson's and Alzheimer's, while Dermavant Sciences focuses on dermatology and Enzyvant Therapeutics concentrates on rare genetic diseases. Roivant Sciences has also raised a considerable amount of capital to finance its various companies. In 2017, the company raised $1.1 billion, expanding its presence in the global healthcare market. Products developed by Roivant Sciences' subsidiaries include Axovant's Nelotanserin, a potential medication for hallucinations and nightmares in Parkinson's patients, as well as Myovant's Leuprolide, a medication for treating prostate cancer. The company also has a partnership with Dartmouth College to advance research and development in neuroscience. The partnership aims to identify "specific molecular targets" for developing treatments for neurodegenerative diseases. In summary, Roivant Sciences Ltd is an innovative biopharmaceutical company that develops orphan molecules and specializes in various therapy areas. Its subsidiaries develop products for a range of diseases, from Alzheimer's to prostate cancer and rare genetic disorders. The company has raised a significant amount of capital to finance its operations and collaborates with academic institutions to advance its research and development. Roivant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.